Study Sheds Light on Pregnancy Complications and Overturns Common Belief

New York—July 3, 2012 

A study led by Hospital for Special Surgery researchers has demonstrated that women who have a specific type of antibody that interferes with blood vessel function are at risk for adverse pregnancy outcomes and that other antibodies in the same family thought to cause pregnancy complications do not put women at risk.

The researchers say that many doctors may be unnecessarily treating some pregnant women who have antiphospholipid antibodies (aPLs) with anticoagulants, such as expensive heparin injections, which can cause bleeding and bone loss. The multicenter study appears in the July 2012 issue of the journal Arthritis & Rheumatism.

“This paper identifies people who are at risk for pregnancy loss and, more importantly, those who are not at risk and who therefore do not need to be treated,” said Michael Lockshin, M.D., director, Barbara Volcker Center for Women and Rheumatic Disease, and co-director, Mary Kirkland Center for Lupus Research at Hospital for Special Surgery (HSS), New York City, and lead author of the study.

Antiphospholipid antibodies interfere with phospholipids, a type of fat found in all living cells and cell membranes, including blood cells and the lining of blood vessels. Patients with these antibodies are at risk for blood clots, stroke, and pregnancy complications, but some patients with these antibodies can be completely healthy. “Phospholipids are highly exposed in the placenta, and as a result antiphospholipid antibodies concentrate there,” said Jane Salmon, M.D., the study's senior author and Collette Kean Research Chair and co-director, Mary Kirkland Center for Lupus Research at HSS. “When antibodies are deposited in a person’s tissues, inflammation is initiated leading to organ damage.” And this is a mechanism for pregnancy complications.

Women who have recurrent pregnancy loss are commonly tested for the presence of aPLs, and up to 15% are positive. Most patients who test positive are treated with anticoagulants. Currently, there are no standards regarding which aPLs doctors test for to assess risk (there are three main ones) and inter-laboratory consistency of results is poor.

The new study is the first clinical research publication of the PROMISSE study, an ongoing multicenter, prospective clinical trial comparing the pregnancies of women with aPL, lupus, both aPL and lupus, and healthy controls. Between 20% and 35% of patients with lupus and aPL have pregnancy complications and the study is attempting to identify which patients are at risk.

“The identification of biomarkers that identify patients at high risk will allow us to select a subset of patients who we can consider in an interventional trial,” said Dr. Salmon, the principal investigator of PROMISSE. This PROMISSE study, which involves over 700 patients from nine centers in North America, is funded by the National Institute of Arthritis, Musculoskeletal and Skin Diseases of the National Institutes of Health. A strength of PROMISSE is that all aPL tests were sent to core laboratories, eliminating inter-laboratory variability.

The current analysis focused on 144 patients who had aPLs, of whom 28 had adverse pregnancy outcomes.  A control group, 159 healthy pregnant women, was tested parallel to the group with aPLs. Controls were selected among women with no known illness, no prior fetal loss, no more than one miscarriage and at least one successful pregnancy.

The study examined the association between adverse pregnancy outcome and the presence of three different aPLs: lupus anticoagulant [LAC], anticardiolipin antibody [aCL] and antibody to ß2 glycoprotein I. An adverse pregnancy outcome was defined as otherwise unexplained fetal death after 12 weeks, neonatal death prior to discharge that was associated with complications of prematurity, preterm delivery prior to 34 weeks because of gestational hypertension, preeclampsia or placental insufficiency, and birthing a child that was small for its gestational age.

The researchers found that LAC was the strongest predictor of an adverse pregnancy outcome; 39% of patients with LAC had an adverse outcome compared to 3% who did not have LAC (P<0.0001). Only 8% of women with aCL, but not LAC, suffered an adverse outcome. Other aPLs did not increase risk. “Lupus anticoagulant is the most important predictor of risk and high titer anticardiolipin antibodies alone don’t provide substantial risk,” said Dr. Salmon. She noted that prior to this study, many physicians considered aCL as a potent predictor of risk.

Anticoagulant treatments are currently used for many women with aPLs, but identifying who to treat is not clear and this treatment is often ineffective.  “Although many patients with aPLs are treated with heparin, pregnancy outcomes are still disappointing. We need better therapies,” said Dr. Salmon. “This study will allow us to identify subsets of patients with the highest risk in whom to test new approaches and new drugs.” 

Dr. Salmon’s studies in mice with aPL have shown that blocking inflammatory pathways can prevent miscarriages, growth restriction and preeclampsia. Further studies on samples from PROMISSE patients, followed by interventional trials will hopefully shed light on whether this therapeutic approach will be effective in pregnant women with aPLs and/or lupus.

Other investigators also involved in the study include Lisa Sammaritano, M.D., from Hospital for Special Surgery; D. Ware Branch, M.D., University of Utah Sciences Center and Intermountain Healthcare, Salt Lake City;  Jill Buyon, M.D., New York University School of Medicine; Carl A. Laskin, M.D., University of Toronto, Toronto; Joan Merrill, M.D., Oklahoma Medical Research Foundation and the University of Oklahoma Sciences Center; Michelle Petri, M.D., MPH, Johns Hopkins University School of Medicine; T Flint Porter, M.D., University of Utah Health Sciences Center and Intermountain Healthcare, Salt Lake City; and Mary Stephenson, M.D., University of Chicago.

About Hospital for Special Surgery
Founded in 1863, Hospital for Special Surgery (HSS) is a world leader in orthopedics, rheumatology and rehabilitation. HSS is nationally ranked No. 1 in orthopedics, No. 2 in rheumatology, No. 19 in neurology, and No. 16 in geriatrics by U.S.News & World Report (2011-12), and is the first hospital in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center three consecutive times. HSS has one of the lowest infection rates in the country. From 2007 to 2011, HSS has been a recipient of the HealthGrades Joint Replacement Excellence Award. HSS is a member of the NewYork-Presbyterian Healthcare System and an affiliate of Weill Cornell Medical College and as such all Hospital for Special Surgery medical staff are faculty of Weill Cornell. The hospital's research division is internationally recognized as a leader in the investigation of musculoskeletal and autoimmune diseases. Hospital for Special Surgery is located in New York City and online at www.hss.edu.
^ Back to Top
Request an Appointment